[go: up one dir, main page]

MA32655B1 - Composés modulant sélectivement le récepteur cb2 - Google Patents

Composés modulant sélectivement le récepteur cb2

Info

Publication number
MA32655B1
MA32655B1 MA33724A MA33724A MA32655B1 MA 32655 B1 MA32655 B1 MA 32655B1 MA 33724 A MA33724 A MA 33724A MA 33724 A MA33724 A MA 33724A MA 32655 B1 MA32655 B1 MA 32655B1
Authority
MA
Morocco
Prior art keywords
receptor
selectively modulating
compounds selectively
compounds
relates
Prior art date
Application number
MA33724A
Other languages
Arabic (ar)
English (en)
Inventor
Brian Nicholas Cook
Darren Disalvo
Daniel Robert Fandrick
Christian Harcken
Daniel Kuzmich
Thomas Wai-Ho Lee
Pingrong Liu
John Lord
Can Mao
Jochen Neu
Brian Christopher Raudenbush
Hossein Razavi
Jonathan Timothy Reeves
Jinhua J Song
Alan David Swinamer
Zhulin Tan
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA32655B1 publication Critical patent/MA32655B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des composés de formule (i), utiles pour le traitement d'une variété de maladies et de troubles qui sont médiés ou prolongés par l'activité de ccr1 qui comprennent des maladies auto-immunes, telles que la polyarthrite rhumatoïde et la sclérose en plaques. La présente invention concerne également des procédés de fabrication et d'utilisation de ces composés.
MA33724A 2008-09-26 2011-03-24 Composés modulant sélectivement le récepteur cb2 MA32655B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10040108P 2008-09-26 2008-09-26
PCT/US2009/057778 WO2010036632A1 (fr) 2008-09-26 2009-09-22 Composés azaindazole en tant qu’antagonistes des récepteurs ccr1

Publications (1)

Publication Number Publication Date
MA32655B1 true MA32655B1 (fr) 2011-09-01

Family

ID=41349302

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33724A MA32655B1 (fr) 2008-09-26 2011-03-24 Composés modulant sélectivement le récepteur cb2

Country Status (24)

Country Link
US (4) US7879873B2 (fr)
EP (1) EP2346868B1 (fr)
JP (1) JP5507567B2 (fr)
KR (1) KR20110060904A (fr)
CN (1) CN102227425A (fr)
AP (1) AP2739A (fr)
AR (1) AR073689A1 (fr)
AU (1) AU2009296839A1 (fr)
BR (1) BRPI0919844A2 (fr)
CA (1) CA2737472A1 (fr)
CL (1) CL2011000668A1 (fr)
CO (1) CO6351735A2 (fr)
EA (1) EA201100524A1 (fr)
EC (1) ECSP11010932A (fr)
IL (1) IL210857A0 (fr)
MA (1) MA32655B1 (fr)
MX (1) MX2011002951A (fr)
NZ (1) NZ591115A (fr)
PE (1) PE20110854A1 (fr)
TW (1) TW201018683A (fr)
UA (1) UA103634C2 (fr)
UY (1) UY32140A (fr)
WO (1) WO2010036632A1 (fr)
ZA (1) ZA201100625B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5216912B2 (ja) 2008-04-29 2013-06-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体拮抗薬としてのインダゾール化合物
CA2722811C (fr) 2008-05-06 2016-07-05 Boehringer Ingelheim International Gmbh Composes de pyrazole comme antagonistes de ccr1
KR20110060904A (ko) 2008-09-26 2011-06-08 베링거 인겔하임 인터내셔날 게엠베하 Ｃｃｒ1 수용체 길항제로서의 아자인다졸 화합물
AU2010224693B2 (en) * 2009-03-19 2016-07-28 Lifearc Compounds
DK2491028T3 (da) 2009-10-21 2014-01-13 Boehringer Ingelheim Int Indazol og pyrazolopyridine forbindelser som CCR1 receptor antagonister
EP2493875B1 (fr) * 2009-10-27 2014-08-06 Boehringer Ingelheim International GmbH Composés hétérocycliques utilisés en tant qu'antagonistes des récepteurs ccr1
IN2012DN05081A (fr) * 2009-12-08 2015-10-09 Boehringer Ingelheim Int
EP2563787B1 (fr) * 2010-04-30 2014-11-26 Boehringer Ingelheim International GmbH Composés azaindazole amides en tant qu'antagonistes des récepteurs ccr1
EP2388260A1 (fr) * 2010-05-21 2011-11-23 Archimica GmbH Procédé de fabrication pour un inhibiteur d'un facteur de coagulation sanguine
AR082885A1 (es) * 2010-09-03 2013-01-16 Genentech Inc Compuestos y composiciones para la inhibicion de nampt
EP2655371B1 (fr) 2010-12-23 2015-02-25 Boehringer Ingelheim International GmbH Composés de pyrazolopipéridine en tant qu'antagonistes de récepteur ccr1
EP2681216B1 (fr) 2011-02-28 2017-09-27 Epizyme, Inc. Composés hétéroaryles bicycliques substitués condensés en 6,5
CN102775365A (zh) * 2011-05-10 2012-11-14 无锡立诺康医药科技有限公司 5-氨基取代基-异噁唑类化合物或其酸式盐的合成工艺
WO2012163848A1 (fr) 2011-05-27 2012-12-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et compositions pharmaceutiques destinés au traitement de la maladie de crohn
WO2013062945A1 (fr) 2011-10-24 2013-05-02 Glaxosmithkline Intellectual Property Development Limited Composés chimiques
EP2771484A1 (fr) 2011-10-28 2014-09-03 Galderma Research & Development Nouveaux marqueurs d'infiltrat leucocytaire de rosacée et utilisations de ceux-ci
JP2015508785A (ja) * 2012-03-02 2015-03-23 ジェネンテック， インコーポレイテッド ピリジニル及びピリミジニルスルホキシド及びスルホン誘導体
AR091858A1 (es) * 2012-07-25 2015-03-04 Sova Pharmaceuticals Inc INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
US9045477B2 (en) * 2013-03-15 2015-06-02 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
EP2970306A4 (fr) * 2013-03-15 2016-08-03 Epizyme Inc Composés hétéroaryles bicycliques substitués condensés en 6,5
FR3016879A1 (fr) * 2014-01-29 2015-07-31 Guillaume Laconde Procede de preparation de benzotriazole n-acyles
SI3119757T1 (en) 2014-03-17 2018-08-31 Pfizer Inc. Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
AP2016009403A0 (en) 2014-04-14 2016-08-31 Boehringer Ingelheim Int Compounds as modulators of ror gamma
CA3002418C (fr) 2015-10-23 2023-10-03 Vifor (International) Ag Nouveaux inhibiteurs de la ferroportine
WO2017081310A1 (fr) 2015-11-13 2017-05-18 Basf Se Oxadiazoles substitués pour lutter contre des champignons phytopathogènes
BR112018009579A2 (pt) 2015-11-13 2018-11-06 Basf Se composto da fórmula i, mistura, composição agroquímica, uso de composto e método de combate a fungos
JP6997095B2 (ja) 2016-03-07 2022-02-03 ザ グローバル アライアンス フォー ティービー ドラッグ デベロップメント， インコーポレイテッド 抗菌性化合物およびその使用
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
TWI853814B (zh) 2018-05-31 2024-09-01 南韓商Ｃ＆Ｃ新藥研究所 雜環衍生物及其用途
CN111393376B (zh) * 2020-05-11 2022-05-13 安徽赛迪生物科技有限公司 一种2-氯嘧啶-4-甲酸的合成方法
WO2021262878A1 (fr) * 2020-06-24 2021-12-30 Oregon Health & Science University Nouvelle molécule pour la modulation de réponses immunitaires innées régulées par une protéine sting

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242931A (en) * 1988-06-09 1993-09-07 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds as TXA2 antagonists
CA1338625C (fr) * 1988-06-09 1996-10-01 Kyowa Hakko Kogyo Co., Ltd. Composes tricycliques
PL170567B1 (pl) 1991-03-28 1997-01-31 Eisai Co Ltd Sposób wytwarzania pochodnych aminy heterocykliczno-cyklicznej PL PL PL PL PL PL PL PL
US5750542A (en) * 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
WO1994001415A1 (fr) * 1992-07-03 1994-01-20 Kumiai Chemical Industry Co., Ltd. Derive heterocyclique condense et desherbant
BR9405488A (pt) * 1993-06-25 1999-06-01 Kumiai Chemical Industry Co Derivado de indazolsulfoniluréia seu uso e intermediário para sua produção
US6025374A (en) * 1994-12-06 2000-02-15 Merck Sharp & Dohme, Ltd. Azetidine, pyrrolidine and piperidine derivatives as 5HT1 receptor agonists
GB9519563D0 (en) 1995-09-26 1995-11-29 Merck Sharp & Dohme Therapeutic agents
GB9523583D0 (en) 1995-11-17 1996-01-17 Merck Sharp & Dohme Therapeutic agents
CA2240439A1 (fr) 1995-12-22 1997-07-03 The Dupont Merck Pharmaceutical Company Nouveaux antagonistes de recepteurs d'integrines
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
JPH101478A (ja) 1996-06-11 1998-01-06 Kumiai Chem Ind Co Ltd インダゾールスルホニル尿素誘導体及び除草剤
GB9615449D0 (en) * 1996-07-23 1996-09-04 Merck Sharp & Dohme Therapeutic agents
WO2000077027A2 (fr) 1999-06-14 2000-12-21 Tularik Limited Composes
EA200000385A1 (ru) 1997-11-04 2000-10-30 Пфайзер Продактс Инк. Терапевтически активные соединения на основе индазольной биоизостерической замены катехина в ингибиторах фосфодиэстеразы типа vi (pde4)
US6331640B1 (en) * 1998-10-13 2001-12-18 Hoffmann-La Roche Inc. Diaminopropionic acid derivatives
ATE303988T1 (de) * 1999-06-14 2005-09-15 Lilly Co Eli Inhibitoren von serin proteasen
AU5895500A (en) * 1999-06-29 2001-01-31 Cor Therapeutics, Inc. Novel indazole peptidomimetics as thrombin receptor antagonists
GB0030303D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030304D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030305D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030306D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US20050009876A1 (en) * 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7058826B2 (en) * 2000-09-27 2006-06-06 Amphus, Inc. System, architecture, and method for logical server and other network devices in a dynamically configurable multi-server network environment
US20020052373A1 (en) 2000-10-26 2002-05-02 Zorn Stevin H. Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease
ES2338539T3 (es) * 2001-11-01 2010-05-10 Icagen, Inc. Pirazolamidas para uso en el tratamiento del dolor.
US20090286791A1 (en) 2001-11-27 2009-11-19 Takeda Pharmaceutical Company Limited Amide Compounds
WO2003053941A2 (fr) * 2001-12-20 2003-07-03 Bristol-Myers Squibb Company Derives de l'acide barbiturique utilises comme inhibiteurs de l'enzyme de conversion du tnf-alpha (tace) et/ou de metalloproteases matricielles
EP1497278B1 (fr) 2002-04-11 2010-05-26 Boehringer Ingelheim Pharmaceuticals Inc. Derives d'amides heterocycliques utilises en tant qu'inhibiteurs de cytokine
IL164209A0 (en) * 2002-05-31 2005-12-18 Eisai Co Ltd Pyrazole derivatives and pharmaceutical compositions containing the same
DK1531822T3 (da) * 2002-06-12 2009-12-07 Chemocentryx Inc 1-aryl-4-substituerede piperazin derivater til anvendelse som CCR1 antagonister til behandlingen af inflammation og immunforstyrrelser
TW200500341A (en) 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0203825D0 (sv) * 2002-12-20 2002-12-20 Astrazeneca Ab Novel fused heterocycles and uses thereof
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
US20040220170A1 (en) * 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
US7371757B2 (en) * 2003-08-15 2008-05-13 Astrazeneca Ab Fused heterocycles as inhibitors of glutamate racemase(MURI)
US7960417B2 (en) 2005-02-24 2011-06-14 Merck Sharp & Dohme Corp. Benzazole potentiators of metabotropic glutamate receptors
GB0504828D0 (en) * 2005-03-09 2005-04-13 Merck Sharp & Dohme Therapeutic agents
PT1881823E (pt) 2005-05-17 2015-03-02 Sarcode Bioscience Inc Composições e métodos para o tratamento de transtornos oculares
US20070010523A1 (en) * 2005-06-22 2007-01-11 Chemocentryx, Inc. Azaindazole compounds and methods of use
AU2006287202B2 (en) 2005-09-01 2013-01-24 Eli Lilly And Company 6-arylalkylamino- 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2c receptor agonists
WO2007102883A2 (fr) 2005-10-25 2007-09-13 Smithkline Beecham Corporation Composés chimiques
TW200829578A (en) * 2006-11-23 2008-07-16 Astrazeneca Ab Chemical compounds 537
WO2009006404A2 (fr) * 2007-06-29 2009-01-08 Sunesis Pharmaceuticals, Inc. Composés hétérocycliques utiles en tant qu'inhibiteurs de la kinase raf
EP2188295A4 (fr) 2007-08-10 2011-11-16 Crystalgenomics Inc Dérivés de pyridine et leurs procédés d'utilisation
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
WO2009085256A1 (fr) * 2007-12-27 2009-07-09 Panacos Pharmaceuticals, Inc. Composés anti-vih
JP5216912B2 (ja) * 2008-04-29 2013-06-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体拮抗薬としてのインダゾール化合物
CA2722811C (fr) 2008-05-06 2016-07-05 Boehringer Ingelheim International Gmbh Composes de pyrazole comme antagonistes de ccr1
KR20110060904A (ko) 2008-09-26 2011-06-08 베링거 인겔하임 인터내셔날 게엠베하 Ｃｃｒ1 수용체 길항제로서의 아자인다졸 화합물
DK2491028T3 (da) 2009-10-21 2014-01-13 Boehringer Ingelheim Int Indazol og pyrazolopyridine forbindelser som CCR1 receptor antagonister
EP2493875B1 (fr) 2009-10-27 2014-08-06 Boehringer Ingelheim International GmbH Composés hétérocycliques utilisés en tant qu'antagonistes des récepteurs ccr1
IN2012DN05081A (fr) * 2009-12-08 2015-10-09 Boehringer Ingelheim Int
EP2563787B1 (fr) 2010-04-30 2014-11-26 Boehringer Ingelheim International GmbH Composés azaindazole amides en tant qu'antagonistes des récepteurs ccr1
EP2655371B1 (fr) 2010-12-23 2015-02-25 Boehringer Ingelheim International GmbH Composés de pyrazolopipéridine en tant qu'antagonistes de récepteur ccr1

Also Published As

Publication number Publication date
UY32140A (es) 2010-04-30
US8063065B2 (en) 2011-11-22
US20100093724A1 (en) 2010-04-15
CL2011000668A1 (es) 2011-10-28
US8163918B2 (en) 2012-04-24
IL210857A0 (en) 2011-04-28
ZA201100625B (en) 2011-09-28
TW201018683A (en) 2010-05-16
UA103634C2 (en) 2013-11-11
AP2011005685A0 (en) 2011-04-30
CA2737472A1 (fr) 2010-04-01
NZ591115A (en) 2012-10-26
US8338610B2 (en) 2012-12-25
CO6351735A2 (es) 2011-12-20
JP5507567B2 (ja) 2014-05-28
US20110086846A1 (en) 2011-04-14
US7879873B2 (en) 2011-02-01
US20120136158A1 (en) 2012-05-31
BRPI0919844A2 (pt) 2019-09-24
AR073689A1 (es) 2010-11-24
JP2012503664A (ja) 2012-02-09
KR20110060904A (ko) 2011-06-08
AP2739A (en) 2013-09-30
AU2009296839A1 (en) 2010-04-01
PE20110854A1 (es) 2011-12-23
CN102227425A (zh) 2011-10-26
EA201100524A1 (ru) 2011-10-31
EP2346868A1 (fr) 2011-07-27
MX2011002951A (es) 2011-04-26
WO2010036632A1 (fr) 2010-04-01
US20120035370A1 (en) 2012-02-09
EP2346868B1 (fr) 2016-01-27
ECSP11010932A (es) 2011-04-29

Similar Documents

Publication Publication Date Title
MA32655B1 (fr) Composés modulant sélectivement le récepteur cb2
MA31521B1 (fr) Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central
MA31147B1 (fr) 4-phenyl-pyrane-3.5-diones ,4-phenyl-thiopyrane-3.5- diones et cyclohexanetriones en tant que nouveaux herbicides
MA30798B1 (fr) Thiazole pyrazolopyrimidines comme antigonistes du recepteur crf1
MA31949B1 (fr) Dérivés d'aminotriazole comme agonistes d'alx
GB0510143D0 (en) Novel compounds A1
UA87856C2 (ru) Алкильные производные как модуляторы метаботропных рецепторов глутамата
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
ATE423769T1 (de) Fluor- und sulfonylaminohaltige, 3,6- disubstituierte azabicyclo 3.1.0 hexanderivate als muscarinrezeptorantagonisten
MA31016B1 (fr) Composes de diazepan substitues comme antagonistes des recepteurs de l'orexine.
TNSN06300A1 (fr) Derives d'imidazole pour le traitement de troubles neurodegeneratifs
MA31470B1 (fr) Dérivés de pipéridine utiles comme antagonistes vis-à-vis des récepteurs de l'orexine
GB0510141D0 (en) Novel compounds B3
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MA33242B1 (fr) Composes pour le traitement de troubles metaboliques
EP1796678A4 (fr) Carboxamide spirolactam cgrp receptor antagonists
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
MA47447A (fr) 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer
MA35419B1 (fr) Inhibiteurs de la tyrosine kinase de bruton
GB0325956D0 (en) Novel compounds
MXPA04001940A (es) Tratamiento para desordenes del sistema nervioso central.
EA200601798A1 (ru) Замещенные соединения морфолина для лечения расстройств центральной нервной системы
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA32506B1 (fr) Nouveaux composes